

REMARKS

Status

Upon entry of amendments, Claims 1-4, 6-9, and 13-22 will be pending in this application. Claims 1-4 and 6 have been amended. Support for the amendments can be found in the original claims and throughout the specification. No new matter will be added upon entry of this amendment.

Claim 12 is withdrawn from consideration. Applicants reserve the right to rejoin Claim 12 according to the direction of MPEP 821.04.


Rejection under 35 USC §112

The rejections of Claims 1-4 and 6 under 35 U.S.C. §112, 1st paragraph has been obviated by appropriate amendment. Withdrawal of this rejection is respectfully requested.

In view of the foregoing, Applicants submit that the application is now in condition for allowance. Early notification of such action is earnestly solicited. If the Examiner has any questions or believes further discussion will aid examination and advance prosecution of the application, a telephone call to the undersigned is invited.

Respectfully submitted,

Date: January 11, 2005



Jing G. Sun, Ph.D.
Agent for Applicants
Registration No. 45,914

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-3791 (phone)
(609) 252-4526 (fax)